BRIEF-Gilead requests FDA pull orphan drug designation from potential coronavirus drugReuters | Updated: 25-03-2020 23:26 IST | Created: 25-03-2020 23:08 IST
Gilead Sciences Inc: * Says requested the U.S. FDA rescind the orphan drug designation it was granted for potential coronavirus drug remdesivir
* Says waiving all benefits that accompany orphan drug designation for remdesivir * Says confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir Further company coverage:
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Download The Devdiscourse News App for Latest News.